{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/TRDA/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-14T23:54:08.314Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":10719,"canonical_name":"Entrada Therapeutics, Inc.","cik":"0001689375","uei":null,"lei":null,"duns":null,"ticker":"TRDA"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":31,"clinical":2},"count":33,"timeline":[{"ts":"2026-09-09","kind":"sec.filing","form_type":"4","title":"4 — Entrada Therapeutics, Inc. — 2026-09-09","url_slug":"/sec/cik-0001689375/4/0001231919-26-001156","accession_number":"0001231919-26-001156","importance":30},{"ts":"2026-09-03","kind":"sec.filing","form_type":"4","title":"4 — Entrada Therapeutics, Inc. — 2026-09-03","url_slug":"/sec/cik-0001689375/4/0001231919-26-001144","accession_number":"0001231919-26-001144","importance":30},{"ts":"2026-09-03","kind":"sec.filing","form_type":"4","title":"4 — Entrada Therapeutics, Inc. — 2026-09-03","url_slug":"/sec/cik-0001689375/4/0001725663-26-000007","accession_number":"0001725663-26-000007","importance":30},{"ts":"2026-09-03","kind":"sec.filing","form_type":"4","title":"4 — Entrada Therapeutics, Inc. — 2026-09-03","url_slug":"/sec/cik-0001689375/4/0001873392-26-000006","accession_number":"0001873392-26-000006","importance":30},{"ts":"2026-09-03","kind":"sec.filing","form_type":"4","title":"4 — Entrada Therapeutics, Inc. — 2026-09-03","url_slug":"/sec/cik-0001689375/4/0001873394-26-000005","accession_number":"0001873394-26-000005","importance":30},{"ts":"2026-08-31","kind":"sec.filing","form_type":"4","title":"4 — Entrada Therapeutics, Inc. — 2026-08-31","url_slug":"/sec/cik-0001689375/4/0001231919-26-001136","accession_number":"0001231919-26-001136","importance":30},{"ts":"2026-08-26","kind":"sec.filing","form_type":"4","title":"4 — Entrada Therapeutics, Inc. — 2026-08-26","url_slug":"/sec/cik-0001689375/4/0001231919-26-001106","accession_number":"0001231919-26-001106","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Entrada Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001689375/schedule-13g-a/0001193125-26-352315","accession_number":"0001193125-26-352315","importance":30},{"ts":"2026-08-05","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Entrada Therapeutics, Inc. — 2026-08-05","url_slug":"/sec/cik-0001689375/10-q/0001689375-26-000054","accession_number":"0001689375-26-000054","importance":45},{"ts":"2026-08-05","kind":"sec.filing","form_type":"8-K","title":"8-K — Entrada Therapeutics, Inc. — 2026-08-05","url_slug":"/sec/cik-0001689375/8-k/0001689375-26-000052","accession_number":"0001689375-26-000052","importance":35},{"ts":"2026-07-31","kind":"sec.insider.s","reporter":"5AM Ventures V, L.P.","title":"","shares":1718,"price_per_share":6.85,"usd_value":11768,"security_title":"Common Stock","importance":35.0117683},{"ts":"2026-07-31","kind":"sec.insider.s","reporter":"5AM Partners V, LLC","title":"","shares":1718,"price_per_share":6.85,"usd_value":11768,"security_title":"Common Stock","importance":35.0117683},{"ts":"2026-07-31","kind":"sec.insider.s","reporter":"5AM Opportunities I, L.P.","title":"","shares":1718,"price_per_share":6.85,"usd_value":11768,"security_title":"Common Stock","importance":35.0117683},{"ts":"2026-07-31","kind":"sec.insider.s","reporter":"5AM Opportunities I (GP), LLC","title":"","shares":1718,"price_per_share":6.85,"usd_value":11768,"security_title":"Common Stock","importance":35.0117683},{"ts":"2026-07-31","kind":"sec.insider.s","reporter":"ROCKLAGE SCOTT M","title":"","shares":1718,"price_per_share":6.85,"usd_value":11768,"security_title":"Common Stock","importance":35.0117683},{"ts":"2026-07-31","kind":"sec.insider.s","reporter":"Schwab Andrew J.","title":"","shares":1718,"price_per_share":6.85,"usd_value":11768,"security_title":"Common Stock","importance":35.0117683},{"ts":"2026-07-31","kind":"sec.insider.s","reporter":"PARMAR KUSH","title":"","shares":1718,"price_per_share":6.85,"usd_value":11768,"security_title":"Common Stock","importance":35.0117683},{"ts":"2026-07-30","kind":"sec.insider.s","reporter":"5AM Ventures V, L.P.","title":"","shares":114756,"price_per_share":6.93,"usd_value":795259,"security_title":"Common Stock","importance":35.79525908},{"ts":"2026-07-30","kind":"sec.insider.s","reporter":"5AM Partners V, LLC","title":"","shares":114756,"price_per_share":6.93,"usd_value":795259,"security_title":"Common Stock","importance":35.79525908},{"ts":"2026-07-30","kind":"sec.insider.s","reporter":"5AM Opportunities I, L.P.","title":"","shares":114756,"price_per_share":6.93,"usd_value":795259,"security_title":"Common Stock","importance":35.79525908},{"ts":"2026-07-30","kind":"sec.insider.s","reporter":"5AM Opportunities I (GP), LLC","title":"","shares":114756,"price_per_share":6.93,"usd_value":795259,"security_title":"Common Stock","importance":35.79525908},{"ts":"2026-07-30","kind":"sec.insider.s","reporter":"ROCKLAGE SCOTT M","title":"","shares":114756,"price_per_share":6.93,"usd_value":795259,"security_title":"Common Stock","importance":35.79525908},{"ts":"2026-07-30","kind":"sec.insider.s","reporter":"Schwab Andrew J.","title":"","shares":114756,"price_per_share":6.93,"usd_value":795259,"security_title":"Common Stock","importance":35.79525908},{"ts":"2026-07-30","kind":"sec.insider.s","reporter":"PARMAR KUSH","title":"","shares":114756,"price_per_share":6.93,"usd_value":795259,"security_title":"Common Stock","importance":35.79525908},{"ts":"2026-07-02","kind":"clinical.trial","reporter":"Entrada Therapeutics, Inc.","title":"Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07682129","excerpt":"[\"Duchenne Muscular Dystrophy (DMD)\"]","importance":45},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Entrada Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001689375/4/0002013423-26-000002","accession_number":"0002013423-26-000002","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Entrada Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001689375/4/0001689375-26-000034","accession_number":"0001689375-26-000034","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Entrada Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001689375/4/0001689375-26-000043","accession_number":"0001689375-26-000043","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Entrada Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0001689375/8-k/0001104659-26-072326","accession_number":"0001104659-26-072326","importance":35},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — Entrada Therapeutics, Inc. — 2026-05-21","url_slug":"/sec/cik-0001689375/4/0001689375-26-000030","accession_number":"0001689375-26-000030","importance":30},{"ts":"2026-05-20","kind":"sec.insider.p","reporter":"Zeiher Bernhardt G","title":null,"shares":5000,"price_per_share":5.8632,"usd_value":29316,"security_title":"Common Stock","importance":50.029316},{"ts":"2026-05-19","kind":"sec.filing","form_type":"8-K","title":"8-K — Entrada Therapeutics, Inc. — 2026-05-19","url_slug":"/sec/cik-0001689375/8-k/0001104659-26-063325","accession_number":"0001104659-26-063325","importance":35},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"Entrada Therapeutics, Inc.","title":"A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07038824","excerpt":"[\"Duchenne Muscular Dystrophy (DMD)\"]","importance":45}]}